| SAVARA INC. DL-,001 |
| USA |
| Gesundheit |
| US8051111016 / A2DQ2B |
| YB4P (Frankfurt) / SVRA (NASDAQ) |
| FRA:YB4P, ETR:YB4P, YB4P:GR, NASDAQ:SVRA |
| - |
| https://savarapharma.com/ |
|
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular ..
>Volltext.. |
| 1048.5 Mio. EUR |
| 960.84 Mio. EUR |
| - |
| -142.87 Mio. EUR |
| -139.32 Mio. EUR |
| -0.56 EUR |
| 27.7 Mio. EUR |
| 27.19 Mio. EUR |
| -118.87 Mio. EUR |
| 7.8 |
| - |
| -36.81% |
| - |
| - |
| - |
| - |
| SAVARA |
| 20.11.26 |
|